ArticleImmunoTargets and therapy2026
UVB Upregulates Inflammatory Cytokines in Rosacea Cell Model by Promoting the Expression of TRPVs and TLR2.
Article in ImmunoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic progress in rosacea: targeting the neuro-vascular-immune triad.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The expression of transient receptor potential vanilloid (TRPV) and Toll-like receptor 2 (TLR2) in the lesion sites of patients with rosacea is increased. Ultraviolet B (UVB) radiation can induce inflammation of keratinocytes in patients with rosacea, but the relationships between UVB and TRPVs/TLR2 in rosacea remain unclear. Methods: RT-qPCR and Western Blot were applied to determine the expression levels of TRPV1, TRPV2, TRPV3, TRPV4 and TLR2 in the rosacea keratinocyte model after ultraviolet irradiation (n=3). After treating the rosacea cell model with TRPV1, TRPV4 and TLR2 inhibitors, ELISA was used to detect the expressions of rosacea-associated inflammatory cytokines in rosacea cells exposed to UVB, including IL-1β, IL-6, IL-8 and TNF-α (n=6). The changes in DNA methylation levels of TRPV1, TRPV4 and TLR2 promoters were detected by MeDIP, and the levels of histone modifications H3K4me3, H3K9me3 and H3K27me3 were determined by ChIP (n=3). Results: UVB exposure increases the secretion levels of rosacea-associated inflammatory cytokines in HaCaT cells and LL-37-induced rosacea keratinocyte models, and promotes the expression of TRPV1, TRPV4 and TLR2 at mRNA and protein levels (P < 0.05). In the LL-37-induced HaCaT cell model, TRPV1 and TLR2 antagonists reduced the secretion levels of IL-1β and IL-8, and TRPV4 antagonists reduced IL-6 secretion level (P < 0.05). Under UVB exposure, TRPV4 and TLR2 antagonists respectively reduced the concentrations of IL-1β and TNF-α in the HaCaT cells stimulated by LL-37 (P < 0.05). In addition, UVB exposure increased the H3K4me3 level of the TRPV1 promoter region in HaCaT cells treated by LL-37 (P < 0.05). Conclusion: Our results indicate that UVB induces inflammatory cytokines in rosacea keratinocyte models through upregulation of TRPV1, TRPV4, and TLR2 expression, potentially mediated by epigenetic mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.